With a global pandemic and a fraught trade war, many are wondering if China’s pharmaceutical monopoly presents a national security threat.
WASHINGTON — The baby had so many pustules ravaging his face he could barely open his right eye, a photograph that left the president, national security adviser and close aides nearly speechless with horror.
A global pandemic had begun in a hospital in Oklahoma City. Doctors soon diagnosed smallpox, a virulent, deadly and disfiguring infection that had disappeared from the planet two decades before. What would the president do?
This was the scenario that a cast of Washington power playe
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from David Barboza, Pulitzer Prize-winning former Shanghai correspondent for The New York Times.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
Washington’s $370 billion Inflation Reduction Act was seen as a generational opportunity for miners in the U.S. as well as mineral rich trading partners. But almost two years later, the North American mining industry is in crisis and no closer to chipping away at China's dominance. What went wrong?
The academic explains why we need to look beyond the actions of the Chinese government to understand how and why China is shaping countries in the region.
Navigate China's Business Landscape with Confidence.